ストックスクリーナーアプリを入手
2.49
2.26%
0.055
アフターアワーズ：
2.47
-0.02
-0.80%
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Eledon Pharmaceuticals (ELDN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026Slideshow (NASDAQ:ELDN) 2026-09-22 - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Shares Rise on Positive Tegoprubar - GuruFocus
Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) - Seeking Alpha
Eledon Gains 13% on Updated Phase 2 Trial Data - Orange County Business Journal
Eledon Pharmaceuticals (ELDN) Advances Tegoprubart Trials with F - GuruFocus
Eledon Pharmaceuticals, Inc. (ELDN) stock price, news, quote and history - uk.finance.yahoo.com
Eledon’s tegoprubart shows kidney function advantage in phase 2 trial - Investing.com
Eledon’s tegoprubart shows kidney function advantage in phase 2 trial By Investing.com - Investing.com India
No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan
ELDN Should I Buy - intellectia.ai
A treatment to prevent kidney transplant rejection will be presented Sept. 22 - Stock Titan
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - The Manila Times
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart - marketscreener.com
Eledon submits IND for tegoprubart islet cell transplant study - investing.com
12 people with type 1 diabetes no longer needed insulin after transplants. Three more are joining. - Stock Titan
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - The Manila Times
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceNAAIM Leverage - dars.gov.et
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureMerger Arbitrage - vinanet.vn
Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen - MarketBeat
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Breakout Confirmation - vinanet.vn
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals (ELDN) - Zacks Investment Research
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Eledon Q2 EPS misses estimates as net loss widens 182% YoY - scanx.trade
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3 - Stock Titan
Eledon Islet Study: All 12 Patients Reached Insulin Independence - Stock Titan
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Meets Mild Share UptickInterim Report - vinanet.vn
Eledon Pharmaceuticals (ELDN) Holds Above $3.60 Support After Modest AdvanceAnchored VWAP - vinanet.vn
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEPS Surprise History - careplusvn.com
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Eledon Pharmaceuticals (ELDN) Institutional Ownership 2026 - MarketBeat
Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday - MarketBeat
ELDN Q2'26 Earnings: EPS estimate is (0.16) USD - TradingView
Eledon Pharmaceuticals (ELDN) Gains 2.19% as Shares Trade Between Key LevelsMoving Average Ribbon - careplusvn.com
Eledon Pharmaceuticals Inc. (ELDN) Q1 2026 Earnings: EPS Misses Estimates by 77.23% as Stock Declines - dars.gov.et
Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADAR1 Capital Management LLC Has $3 Million Position in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
Eledon Pharmaceuticals Inc (ELDN) Cash Flow - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELDN - TradingView
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - webull.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eledon’s BESTOW Trial Completion: What Tegoprubart Could Mean for Transplant Investing - TipRanks
Eledon Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesRevenue Breakdown Analysis - dars.gov.et
ELDN Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):